Human T lymphocytes were engineered with a lentiviral vector to express anti-FRα-CAR5, which incorporates a fourth-generation CAR backbone (CD28, 4-1BB, CD27, and CD3 zeta) augmented by a secreted anti-PD-L1 scFv derived from atezolizumab...This fifth-generation CAR offers a promising strategy to enhance CAR T cell therapy efficacy in PD-L1-mediated immunosuppressive TMEs. These findings suggest that anti-FRα-CAR5 T cells therapy warrants further preclinical validation as a potential treatment strategy for NSCLC patients.

These findings establish KN035-MS as a synergistic adjunct to TACE, addressing both inefficient drug delivery and postembolization immune evasion. This dual-mechanism strategy provides a clinically translatable approach to mitigate HCC recurrence, warranting further investigation in combinatorial locoregional-immunotherapy paradigms.

The necrotic lesion possibly had a hepatocellular carcinoma component, and the liver cancer before Atezo/Bev treatment was possibly a combined hepatocellular-cholangiocarcinoma or cholangiolocellular carcinoma. The patient died of parkinsonism 1 year after surgery, without recurrence of liver cancer.

P1/2, N=103, Suspended, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Jul 2027 | Trial primary completion date: Dec 2025 --> Jul 2027

cGAS functions as a dual biomarker, predicting poor prognosis after hepatectomy but favorable response to immunotherapy. These findings underscore the clinical relevance of cGAS and its potential to guide personalized HCC treatment.

Primary and secondary pseudo-stability/progression occur in a non-trivial proportion of patients across cancer types. Outcomes after pseudo-stability/progression are dependent on cancer type and initial response. Uncovering the clinical and molecular features of pseudo-stability/progression subtypes may guide treatment decisions and identify patients who may benefit from continued immunotherapy despite radiographic progression.

Compared with atezolizumab monotherapy, a combination of chemotherapy, atezolizumab, and bevacizumab led to dramatically improved progression-free survival in patients with mismatch repair-deficient /microsatellite instability-high metastatic colorectal cancer. Because these patients often experience disease progression on immunotherapy, the results suggest that the combination approach could improve how they fare.

Tumor-intrinsic activation of the NRF2-COX2-PGE₂ axis drives immune cold TMEs and mediates Atez/Bev resistance in HCC. Targeting this pathway may enhance efficacy, and plasma PGE₂ represents a non-invasive biomarker for stratification.

This case suggests that an integrated approach, combining aggressive local therapy with systemic immunotherapy informed by biomarkers, can achieve a favorable outcome in selected patients with ICC. The identification of a high tumor mutational burden was crucial in guiding treatment and supports its potential as a predictive biomarker. This precision oncology strategy may improve the poor prognosis associated with this condition.

P=N/A, N=236, Completed, AstraZeneca | Active, not recruiting --> Completed | Trial completion date: Jul 2026 --> Nov 2025 | Trial primary completion date: Jul 2026 --> Nov 2025

P1/2, N=18, Completed, Kristoffer Rohrberg | Recruiting --> Completed | N=39 --> 18

P3, N=1280, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Aug 2035 --> Dec 2027